Wall Street analysts forecast that Abeona Therapeutics Inc. (NASDAQ:ABEO) will announce ($0.16) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Abeona Therapeutics’ earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.20). Abeona Therapeutics reported earnings of ($0.08) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 100%. The firm is expected to announce its next quarterly earnings report on Monday, November 13th.

On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.66) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.51). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.73) per share, with EPS estimates ranging from ($0.84) to ($0.59). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.21 million.

A number of research firms recently issued reports on ABEO. Maxim Group set a $14.00 price target on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 25th. FBR & Co restated a “buy” rating on shares of Abeona Therapeutics in a report on Friday, May 26th. Jefferies Group LLC restated a “buy” rating and issued a $11.00 price objective on shares of Abeona Therapeutics in a report on Thursday, June 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a report on Tuesday, June 6th. Finally, Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $18.50.

Shares of Abeona Therapeutics (NASDAQ:ABEO) traded down 8.64% during mid-day trading on Friday, hitting $14.80. The stock had a trading volume of 768,804 shares. Abeona Therapeutics has a 1-year low of $4.05 and a 1-year high of $17.90. The stock’s 50-day moving average is $10.74 and its 200 day moving average is $7.22. The firm’s market capitalization is $596.25 million.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Private Advisor Group LLC lifted its holdings in Abeona Therapeutics by 50.0% during the 1st quarter. Private Advisor Group LLC now owns 21,005 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 6,999 shares in the last quarter. Family Management Corp bought a new stake in shares of Abeona Therapeutics in the 1st quarter valued at about $120,000. State of Wisconsin Investment Board bought a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at about $122,000. Segantii Capital Management Ltd raised its holdings in shares of Abeona Therapeutics by 564.6% in the 1st quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 28,794 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at about $190,000. Institutional investors own 38.24% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Abeona Therapeutics Inc. (ABEO) Expected to Announce Earnings of -$0.16 Per Share” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/22/abeona-therapeutics-inc-abeo-expected-to-announce-earnings-of-0-16-per-share.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.